Evelyn Partners’s Novartis NVS Stock Holding History

Evelyn Partners’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$110K	Buy	+700	New	+$105K	﹤0.01%	309

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Natixis Advisors Boston, Massachusetts $88.9B AUM 38.03% 1-Year Est. Return

Evelyn Partners's NVS Position: Q2 2026 in Review

Evelyn Partners opened a new position in Novartis (NVS) in Q2 2026: 700 shares worth $110K. The stake represents ﹤0.01% of the portfolio and ranks #309 among its holdings.

1,546 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

Evelyn Partners held 700 shares of Novartis worth $110K as of Q2 2026.
Novartis was a new Evelyn Partners position in Q2 2026.
Novartis made up ﹤0.01% of Evelyn Partners's portfolio in Q2 2026, its #309 holding.
1,546 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Evelyn Partners's 13F filing for Q2 2026, filed 7 Aug 2026.